Welnox, a Martin Dow Group company, has entered into a licensing partnership with Procter & Gamble (P&G) for Vicks VapoRub.

The company expects the product to become available across Pakistan in the coming weeks.

The partnership supports Martin Dow’s strategy to expand access to healthcare products for consumers across the country.

Vicks VapoRub Brings More Than 125 Years of Heritage

Vicks has remained part of family healthcare routines for generations.

The brand has more than 125 years of heritage in consumer healthcare.

Vicks VapoRub is formulated to provide relief from common cold symptoms, including nasal congestion, cough, headache and body aches.

The product also aims to provide comfort for breathing-related discomfort associated with colds.

Welnox Targets Consumer Healthcare Growth

Welnox CEO Anwar Zaman said Vicks VapoRub fits the company’s consumer-focused healthcare strategy.

GREE Ranked World’s No. 1 Premium Residential AC Brand

“Vicks VapoRub is an iconic brand with enduring equity, and a natural fit with our vision to build a strong, consumer-centric healthcare portfolio,” Zaman said.

He added that Welnox sees an opportunity to build on the brand’s existing strength and create new growth opportunities in Pakistan.

Vicks VapoRub to Reach Pharmacies Nationwide

Welnox said Vicks VapoRub will become available at pharmacies across Pakistan in the coming weeks.

The launch will expand access to the well-known consumer healthcare product for Pakistani consumers.

The licensing agreement also marks another step in Martin Dow Group’s efforts to strengthen its healthcare portfolio and expand access to established international brands.